NextGen's targets are based on the most advanced new genetics and bio markers technology that has only been applied to cancer targets recently, and the use of bio markers combined with the prospect of cancer treatment allows for fast tracking with the FDA, cutting down the approval processing by half.
Based on nine years of extensive research by leading scientists at world class facilities using the most advanced technology for bio markers, NextGen is engaged in the development and commercial licensure of novel therapeutic proteins that disrupt the growth of cancers. NextGen`s drug and product portfolio includes a prostate cancer target and a brat cancer target.
NextGen's pipeline of solid tissue cancer targets differ from current methods because they are based on the most up to date bio markers technology. This applied advanced genetics technology has only recently been available. Thus, these pipeline targets are especially promising as they can regenerate benign new cells which will replace and overcome the old malignant cancer cells therefore preventing the need for surgery.
